RNA Avidity Biosciences Inc
Price (delayed)
$41.28
Market cap
$4.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.95
Enterprise value
$3.96B
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in
Highlights
The equity has soared by 118% YoY and by 47% QoQ
RNA's quick ratio is up by 27% from the previous quarter and by 21% YoY
RNA's revenue is up by 8% year-on-year but it is down by 2.5% since the previous quarter
The gross profit rose by 8% YoY but it fell by 2.5% QoQ
RNA's net income is down by 30% YoY and by 10% QoQ
Key stats
What are the main financial stats of RNA
Market
Valuations
Earnings
Shares outstanding
109.8M
Market cap
$4.53B
Enterprise value
$3.96B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.23
Price to sales (P/S)
416.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
373.85
Revenue
$10.6M
EBIT
-$252.45M
EBITDA
-$246.73M
Free cash flow
-$158.91M
Per share
Balance sheet
Liquidity
EPS
-$2.95
Free cash flow per share
-$1.49
Book value per share
$12.77
Revenue per share
$0.1
TBVPS
$12.6
Total assets
$1.35B
Total liabilities
$126.39M
Debt
$8.38M
Equity
$1.22B
Working capital
$1.24B
Debt to equity
0.01
Current ratio
15.78
Quick ratio
15.46
Net debt/EBITDA
2.31
Margins
Efficiency
Dividend
EBITDA margin
-2,327.9%
Gross margin
100%
Net margin
-2,381.8%
Operating margin
-2,690.6%
Return on assets
-28.8%
Return on equity
-32.9%
Return on invested capital
-52.4%
Return on capital employed
-20%
Return on sales
-2,381.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNA stock price
How has the Avidity Biosciences stock price performed over time
Intraday
1.83%
1 week
1.28%
1 month
-7.19%
1 year
472.54%
YTD
356.13%
QTD
1.05%
Financial performance
How have Avidity Biosciences's revenue and profit performed over time
Revenue
$10.6M
Gross profit
$10.6M
Operating income
-$285.18M
Net income
-$252.45M
Gross margin
100%
Net margin
-2,381.8%
The operating income has contracted by 37% YoY and by 12% from the previous quarter
RNA's net income is down by 30% YoY and by 10% QoQ
RNA's operating margin is down by 27% year-on-year and by 15% since the previous quarter
Avidity Biosciences's net margin has decreased by 21% YoY and by 13% from the previous quarter
Growth
What is Avidity Biosciences's growth rate over time
Valuation
What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
3.23
P/S
416.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
373.85
RNA's EPS is up by 5% YoY
The equity has soared by 118% YoY and by 47% QoQ
The P/B is 59% above the last 4 quarters average of 2.0 and 33% above the 5-year quarterly average of 2.4
RNA's P/S is 123% above its last 4 quarters average of 183.2
RNA's revenue is up by 8% year-on-year but it is down by 2.5% since the previous quarter
Efficiency
How efficient is Avidity Biosciences business performance
RNA's ROS is down by 21% YoY and by 13% from the previous quarter
RNA's ROA is up by 15% YoY and by 13% from the previous quarter
The ROE has grown by 13% from the previous quarter and by 12% YoY
RNA's return on invested capital is up by 6% year-on-year and by 5% since the previous quarter
Dividends
What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNA.
Financial health
How did Avidity Biosciences financials performed over time
RNA's total liabilities has surged by 145% year-on-year and by 4.8% since the previous quarter
RNA's total assets has soared by 121% YoY and by 42% QoQ
Avidity Biosciences's debt is 99% less than its equity
The equity has soared by 118% YoY and by 47% QoQ
Avidity Biosciences's debt to equity has plunged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.